A. Ivey

发表

Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study

T. Barbui, S. Schnittger, P. Guglielmelli, 2013, Leukemia.

NUP98‐NSD1 fusion in association with FLT3‐ITD mutation identifies a prognostically relevant subgroup of pediatric acute myeloid leukemia patients suitable for monitoring by real time quantitative PCR

S. Akiki, D. Grimwade, J. Borrow, 2013, Genes, chromosomes & cancer.

ADVANCES IN ACUTE MYELOID LEUKEMIA Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance Cytogenetic analyses of large cohorts of AML patients

D. Grimwade, B. Huntly, A. Ivey, 2015 .

Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low‐intensity chemotherapy in acute myeloid leukaemia

N. Potter, N. Russell, A. Wei, 2020, British journal of haematology.

Molecular MRD status and outcome after transplantation in NPM1 mutated AML: results from the UK NCRI AML17 study.

N. Potter, C. Craddock, R. Hills, 2019, Blood.

University of Birmingham Wilms' Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses

A. Khwaja, E. Morris, H. Stauss, 2013 .

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML.

Qi Zhang, M. Konopleva, K. Patel, 2020, Blood.

Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia

N. Potter, N. Russell, A. Wei, 2021, Blood advances.

Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance.

D. Grimwade, B. Huntly, A. Ivey, 2016, Blood.

Molecular Detection of Minimal Residual Disease Provides the Most Powerful Independent Prognostic Factor Irrespective of Clonal Architecture in Nucleophosmin (NPM1) Mutant Acute Myeloid Leukemia

P. Vyas, M. Simpson, R. Hills, 2014 .

Genetically distinct leukemic stem cells in human CD34− acute myeloid leukemia are arrested at a hemopoietic precursor-like stage

P. Vyas, A. Mead, C. Craddock, 2016, The Journal of experimental medicine.

Assessment of Minimal Residual Disease in Standard-Risk AML.

Yashma Patel, Robert K Hills, Hassan Farah, 2016, The New England journal of medicine.

Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia.

T. Haferlach, R. Hills, S. Schnittger, 2015, Blood.

Genome-wide association study identi ﬁ es susceptibility loci for acute myeloid leukemia

Lara E Sucheston-Campbell, Lara E. Sucheston-Campbell, C. Gieger, 2022 .

Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia

I. Weissman, P. Vyas, C. Craddock, 2013, Leukemia.

Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia

F. Colland, Youzhen Wang, A. Roberts, 2018, Leukemia.

Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy.

S. Bohlander, J. Reynolds, A. Roberts, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Wilms’ Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses

C. Craddock, A. Khwaja, D. Grimwade, 2013, British journal of haematology.

Assessment of Minimal Residual Disease in Standard-Risk AML.

R. Hills, D. Grimwade, A. Ivey, 2016, The New England journal of medicine.

The Cks1/Cks2 axis fine-tunes Mll1 expression and is crucial for MLL-rearranged leukaemia cell viability

T. Haferlach, D. Grimwade, T. Milne, 2018, Biochimica et biophysica acta. Molecular cell research.

The Impact of Sorafenib on Phospho-FLT3 Inhibition and FLT3-ITD MRD after Chemotherapy: Correlative Studies from the Phase 2 Randomized Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16)

P. Marlton, A. Roberts, A. Wei, 2020, Blood.

Molecular MRD Assessment Is Strongly Prognostic in Patients with NPM1 Mutated AML Receiving Venetoclax Based Non-Intensive Therapy

N. Potter, C. Crawley, A. Wei, 2022, Blood.

ALLG AMLM26 Phase 1B/2 Study Investigating Novel Therapies to Target Early Relapse and Clonal Evolution As Pre-Emptive Therapy in AML (INTERCEPT): A Multi-Arm, Precision-Based, Recursive, Platform Trial

M. Konopleva, K. Patel, D. Kipp, 2022, Blood.

A Prospective Phase 2 Study of Venetoclax and Low Dose Ara-C (VALDAC) to Target Rising Molecular Measurable Residual Disease and Early Relapse in Acute Myeloid Leukemia

A. Wei, S. Fleming, I. Tiong, 2021, Blood.

Peripheral blood CD34 donor chimerism has greater clinical utility than CD3 for detecting relapse after allogeneic stem cell transplantation for AML or MDS.

D. Curtis, S. Fleming, A. Spencer, 2023, Transplantation and cellular therapy.

Systematic Evaluation of DNA-Based Quantitative-Polymerase Chain Reaction (Q-PCR) Assays to Track Treatment Response in Patients with JAK2-V617F Associated Myeloproliferative Neoplasms: A Joint European LeukemiaNet/ MPN&MPNr-EuroNet Study

T. Barbui, P. Guglielmelli, A. Pancrazzi, 2011 .

Acute myeloid leukaemia with mutated NPM1 presenting with extensive bone marrow necrosis and Charcot–Leyden crystals

D. Grimwade, D. Culligan, A. Ivey, 2013, International Journal of Hematology.

Pre-Transplant NPM1 Mutant Transcript Level Is Highly Predictive of Outcome after Allograft and Thresholds Are Dependent on FLT3 ITD Status

N. Potter, R. Hills, N. Russell, 2018, Blood.

Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome

N. Potter, N. Russell, A. Wei, 2022, Blood.

Cellular distribution of IDH mutations in AML during morphologic remission.

I. Tiong, A. Ivey, F. Brown, 2022, Leukemia research.

Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia

Lara E. Sucheston-Campbell, C. Gieger, A. Skol, 2022, Nature communications.

Combined BCL-2 and HDAC Targeting Has Potent and TP53 Independent Activity in AML

P. Ekert, A. Wei, L. Kraus-Berthier, 2018, Blood.

PcG methylation of the HIST1 cluster defines an epigenetic marker of acute myeloid leukemia

S. Spicuglia, D. Grimwade, G. Bidaut, 2014, Leukemia.

Anti-Leukemic Activity of Single Agent Venetoclax in Newly Diagnosed Acute Myeloid Leukemia: A Sub-Set Analysis of the Caveat Study

S. Bohlander, J. Reynolds, A. Roberts, 2019, Blood.

Laboratory quality assessment of candidate gene panel testing for acute myeloid leukaemia: a joint ALLG / RCPAQAP initiative.

Anna L. Brown, S. Bohlander, M. Horan, 2020, Pathology.